Medical Pharmacology: Pulmonary Pharmacology Practice Questions
Choose the correct answer for each question.
Which one(s) of the following is/are associated with asthma, chronic airway inflammatory disease?
- Activation of mast cells
- Infiltration of innate type 2 lymphocytes (ILC 2)
- Both
- Neither
Which one(s) of the following is/are associated with asthma, chronic airway inflammatory disease?
- Eosinophil infiltration
- Infiltration of T helper 2 (TH2) lymphocytes.
- Both
- Neither
Consequence(s) of allergen-induced mast cell activation and bronchoconstrictor mediator release?
- Microvascular leakage
- Plasma exudation
- Bronchodilation
- A & B
- B & C
- A & C
- A, B & C
Example(s) of bronchoconstrictor mediators which may be released by physical stimuli
- Prostaglandin D2
- Leukotriene D4 (LTD4)
- Histamine
- A & B
- B & C
- A & C
- A, B & C
Airway smooth muscle contraction appears responsible for the majority of asthma symptoms.
- True
- False
Which one(s) of the following statements is/are correct?
- Multiple inflammatory mediators are released by the airway epithelium.
- Airway epithelium is involved in growth factor release as part of damage repair; damageas a result of inflammation.
- Both
- Neither
Airway consequences due to chronic inflammation:
- More airway smooth muscle cells
- Larger airway smooth muscle cells
- Fewer mucus-secreting cells
- Reduced number of blood vessels
- A & B
- B & C
- A & C
- A, B & C
- A, B, C & D (all responses are correct)
Typical timeframe for asthma onset:
- Early childhood
- Adolescence
- Adulthood
Characteristic(s) of asthma:
- Responsive to corticosteroids and bronchodilators for therapeutic management.
- Associated with variable airflow obstruction
- Characterized by consistent and persistent reduced airflow
- A & B
- B & C
- A & C
- A, B & C
An insidious characteristic of asthma involves progression from mild asthma to severe asthma
- True
- False
If you wish to return to the Table of Contents
in ENGLISH, press the RETURN button above. |
Otherwise, if the text is NOT displayed in
English and you are ready to leave this page,
Press here
to return to the Table of Contents
|